Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) arcticnovartis
https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00arcticnovartishttps://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngarcticnovartis2026-09-04 22:34:492026-09-04 22:34:49Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
